The termination caps the total dilution from this offering at the base 8 million units. Monitor for any subsequent capital raises or financial distress signals given the company's small market cap and pre-revenue status.
Price Chart
Executive Summary
China SXT Pharmaceuticals terminated the over-allotment option from its October 8, 2026 registered direct offering, eliminating the investors' right to purchase up to an additional $12 million of securities. The termination removes potential future dilution of up to 8 million additional shares at $1.50/unit, but the base offering of 8,000,000 units for $12 million remains in effect. This is a modest positive for existing shareholders as it caps the dilution from this offering.
Key Facts
- Terminated over-allotment option allowed investors to purchase up to $12 million additional securities within 30 days of closing
- Base offering of 8,000,000 units at $1.50/unit for total $12 million remains unchanged
- Termination is irrevocable and extinguishes all future rights under Section 2.4 of the purchase agreement
- Press release issued October 21, 2026 announcing the termination
Financial Impact
Removes potential future dilution of up to $12 million (8 million additional shares at $1.50/unit) — a 100% increase over the base offering size. The base offering dilution of $12 million (8 million shares) remains.
Risk Factors
- Base offering of 8 million units at $1.50/unit still represents significant dilution
- Company may still need additional capital given its early-stage pharmaceutical operations
- No financial data provided — company's cash position and burn rate remain unknown
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111404 |
| Document: ea030919801ex10-1.htm | 0001213900-26-111404 |
| Document: ea030919801ex99-1.htm | 0001213900-26-111404 |
| Document: 0001213900-26-111404-index-headers.html | 0001213900-26-111404 |
| Document: 0001213900-26-111404-index.html | 0001213900-26-111404 |
| Document: 0001213900-26-111404.txt | 0001213900-26-111404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $0.0480 | awaiting T+5 | — | $3.55 (+7295.83%) |
Oct 15, 2026 12d ago | SC 13G | $0.0650 $0.0410 | ▼ −36.92% | ▼ −36.49% | $3.55 (+5361.54%) |
Oct 9, 2026 18d ago | 6-K | $0.1020 $0.1112 | ▼ −9.02% | ▼ −10.51% | $3.55 (−3380.39%) |
Oct 9, 2026 18d ago | 424B5 | $0.1487 $0.0650 | ▲ +56.29% | ▲ +54.32% | $3.55 (−2287.36%) |
Oct 8, 2026 19d ago | 6-K | $0.3435 $0.0688 | ▲ +79.97% | ▲ +79.69% | $3.55 (−933.48%) |
Oct 8, 2026 19d ago | 6-K | $0.3435 $0.0688 | ▲ +79.97% | ▲ +79.69% | $3.55 (−933.48%) |
Sep 17, 2026 5w ago | EFFECT | $2.44 $2.55 | ▼ −4.72% | ▼ −4.12% | $3.55 (−45.79%) |
Aug 28, 2026 8w ago | 6-K | $2.56 $2.24 | ▲ +12.50% | ▲ +12.36% | $3.55 (−38.67%) |
Jul 24, 2026 13w ago | 424B5 | $0.0638 $0.0618 | ▲ +3.13% | ▲ +4.23% | $3.55 (−5464.26%) |
Jun 1, 2026 21w ago | 424B5 | $1.78 $1.56 | ▲ +12.36% | ▲ +9.39% | $3.55 (−99.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers